Recognition validates that the course has a
positive impact on students' knowledge of safe prescription drug
use and potential future actions
CHARLESTON, S.C., May 7, 2024
/PRNewswire/ -- EVERFI® from Blackbaud®, the leader in
powering social impact through education, today announced that its
program, Prescription Drug Safety: Know the truth, has been
certified as meeting the evidence-based standards outlined in the
Every Student Succeeds Act (ESSA), aligning with Level III
certification for "Promising Evidence." This certification
demonstrates that usage of the course correlates with students'
personal responsibility, perceived social norms, knowledge of safe
prescription drug use, and potential future actions.
The ESSA certification was awarded through LearnPlatform by
Instructure, following an extensive review of the research study,
"Promoting Prescription Drug Safety Skills in School: Evaluating
the Effectiveness of a Technology-Based Curriculum." The research
study, conducted by Lynch Research Associates, found that compared
to a control group of students, students who took EVERFI's
prescription drug safety course saw:
- Significant growth in personal responsibility for helping to
prevent prescription drug abuse or misuse with others in their
community
- More accurate perceptions of social norms for prescription drug
abuse, misuse, or refusal among peers
- Increased knowledge of prescription drug-related topics
including addiction, safe use of prescriptions, and refusal
skills
- Lower likelihood of engaging in future actions related to
prescription drug abuse or misuse
- Improved refusal skills for rejecting offers of prescription
drugs in situations
Prescription drug misuse among youth aged 12-18 remains high in
the United States with The
National Institute on Drug Abuse indicating that approximately
2,000 teens abuse prescription drugs every single day and upwards
of 3 million youth aged 12-17 admitted to abusing prescription
drugs at least once in their lifetime. Public health experts and
medical providers have been increasingly calling for effective,
evidence-based prescription drug misuse prevention and intervention
programming that reaches large numbers of youth who may be exposed
to opportunities to engage in non-medical prescription drug
use.
"The statistics around prescription drug misuse and abuse are
startling and we cannot deny that as a country, we have reached a
point of crisis and urgent action is needed," said Alice Lee, senior vice president, K-12
implementation, EVERFI from Blackbaud. "One of the clearest ways to
reach the student population with potentially lifesaving
information is through our K-12 school system. We work closely with
leading experts to design and develop our courses and with school
districts to bring them to students nationwide. Certifications like
this are important to validate the program and allow us to bring
this education to more students."
Schools and school districts are increasingly encouraged to use
programs and tools that have been proven, through rigorously
designed research studies, to positively impact student outcomes.
The ESSA Levels of Evidence provide an easy-to-interpret
framework for identifying what programs work. With LearnPlatform,
EVERFI has a respected third-party evidence partner that solidifies
the company's commitment to demonstrating the impact of its
programs for students. EVERFI is committed to continuing to
strengthen its library of evidence and bring high-quality
evidence-based programs to educators in every classroom.
Prescription Drug Safety: Know the truth is a free
digital course that guides teachers and educates youth about the
dangers associated with misusing prescription medications. Through
real-world scenarios, students can recognize the impact
prescription drug misuse can have on their physical and mental
health, relationships, and future. They also learn how to support
others in situations involving prescription drug misuse and
overdose.
Since its launch in 2017, nearly 1.3 million students have
actively engaged with the curriculum, and more than 7,000 schools
have used the course.
For more information or to sign up for the Prescription Drug
Safety: Know the truth course, visit
https://everfi.com/courses/k-12/prescription-drug-safety-high-school/.
About EVERFI from Blackbaud
EVERFI® from
Blackbaud® (NASDAQ: BLKB) is an international technology
company driving social impact through education to address the most
challenging issues affecting society ranging from financial
wellness to mental health to workplace conduct and other critical
topics. Founded in 2008, EVERFI's Impact-as-a-Service™ solution and
digital educational content have reached more than 45 million
learners globally. In 2020, the company was recognized as one of
the World's Most Innovative Companies by Fast Company and was
featured on Fortune Magazine's Impact 20 List. The company was also
named to the 2021 GSV EdTech 150, a list of the most transformative
growth companies in digital learning. Blackbaud acquired
EVERFI in December 2021. To learn
more about EVERFI, please visit everfi.com or follow us
on Facebook, Instagram, LinkedIn, or X/Twitter @EVERFI.
Media Inquiries
Jennifer Edgerly
EVERFI from Blackbaud
jedgerly@everfi.com
Blackbaud Forward-looking Statements
Except for
historical information, all of the statements, expectations, and
assumptions contained in this news release are forward-looking
statements that involve a number of risks and uncertainties,
including statements regarding expected benefits of products and
product features. Although Blackbaud attempts to be accurate in
making these forward-looking statements, it is possible that future
circumstances might differ from the assumptions on which such
statements are based. In addition, other important factors that
could cause results to differ materially include the following:
general economic risks; uncertainty regarding increased business
and renewals from existing customers; continued success in sales
growth; management of integration of acquired companies and other
risks associated with acquisitions; risks associated with
successful implementation of multiple integrated software products;
the ability to attract and retain key personnel; risks associated
with management of growth; lengthy sales and implementation cycles,
particularly in larger organization; technological changes that
make our products and services less competitive; and the other risk
factors set forth from time to time in the SEC filings for
Blackbaud, copies of which are available free of charge at the
SEC's website at www.sec.gov or upon request from Blackbaud's
investor relations department. All Blackbaud product names
appearing herein are trademarks or registered trademarks of
Blackbaud, Inc.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/everfi-from-blackbauds-prescription-drug-safety-course-certified-as-meeting-rigorous-essa-evidence-standards-302136537.html
SOURCE EVERFI